Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
Status
Completed
Conditions
Breast Cancer
Treatments
Other: no intervention
Details and patient eligibility
About
About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.
Enrollment
1,299 patients
Sex
All
Volunteers
No Healthy Volunteers
Inclusion criteria
Patients with available HER2 status of primary breast cancer and relapse/metastases
Exclusion criteria
Patients with other malignancy
Trial design
1,299 participants in 3 patient groups
HER2-0
Treatment:
Other: no intervention
HER2-LOW
Treatment:
Other: no intervention
HER2-POSITIVE
Treatment:
Other: no intervention
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems